A phase I open label dose escalation study to evaluate MEDI-507 in patients with CD2-positive T-cell lymphoma/leukemia.

被引：7

作者：

Casale, Deborah A.

Bartlett, Nancy L.

Hurd, David D.

Foss, Francine

Pro, Barbara

Sokol, Lubomir

Lieberman, Ronald

Luz, Hammershaimb

机构：

[1] Washington Univ, Sch Med, Div Med Oncol, St Louis, MO USA

[2] Wake Forest Univ Hlth Sci, Ctr Comprehens Canc, Winston Salem, NC USA

[3] Yale Canc Ctr, New Haven, CT USA

[4] MD Anderson Canc Ctr, Dept Lymphoma & Myeloma, Houston, TX USA

[5] H Lee Moffitt Canc Ctr & Res Inst, Div Hematol & Oncol, Tampa, FL USA

[6] MedImmune Oncol Inc, Clin Dev, Gaithersburg, MD USA

来源：

关键词：

D O I：

10.1182/blood.V108.11.2727.2727

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

2727

引用

页码：771A / 771A

页数：1